The evaluation of the utility of the GENECUBE HQ SARS-CoV-2 for anterior nasal samples and saliva samples with a new rapid examination protocol

Asami Naito¹, Yoshihiko Kiyasu²,³, Yusaku Akashi²,⁴, Akio Sugiyama⁵, Masashi Michibuchi⁶, Yuto Takeuchi²,³, Shigeyuki Notake⁶, Koji Nakamura⁶, Hiroichi Ishikawa⁷, Hiromichi Suzuki²,³,⁸

¹ Tsukuba i-Laboratory LLP, Tsukuba, Ibaraki, Japan, ² Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan, ³ Department of Infectious Diseases, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan, ⁴ Akashi Internal Medicine Clinic, Kashiwa, Osaka, Japan, ⁵ Diagnostic System Department, TOYOBO Co., Ltd., Kita-ku, Osaka, Japan, ⁶ Department of Clinical Laboratory, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan, ⁷ Department of Respiratory Medicine, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan, ⁸ Department of Infectious Diseases, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan

* hsuzuki@md.tsukuba.ac.jp

Abstract

Introduction

GENECUBE® is a rapid molecular identification system, and previous studies demonstrated that GENECUBE® HQ SARS-CoV-2 showed excellent analytical performance for the detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with nasopharyngeal samples. However, other respiratory samples have not been evaluated.

Methods

This prospective comparison between GENECUBE® HQ SARS-CoV-2 and reference real-time reverse transcriptase polymerase chain reaction (RT-PCR) was performed for the detection of SARS-CoV-2 using anterior nasal samples and saliva samples. Additionally, we evaluated a new rapid examination protocol using GENECUBE® HQ SARS-CoV-2 for the detection of SARS-CoV-2 with saliva samples. For the rapid protocol, in the preparation of saliva samples, purification and extraction processes were adjusted, and the total process time was shortened to approximately 35 minutes.

Results

For 359 anterior nasal samples, the total-, positive-, and negative concordance of the two assays was 99.7% (358/359), 98.1% (51/52), and 100% (307/307), respectively. For saliva samples, the total-, positive-, and negative concordance of the two assays was 99.6% (239/240), 100% (56/56), and 99.5% (183/184), respectively. With the new protocol, total-, positive-, and negative concordance of the two assays was 98.8% (237/240), 100% (56/56), and
98.4% (181/184), respectively. In all discordance cases, SARS-CoV-2 was detected by additional molecular examinations.

**Conclusion**

GENECUBE® HQ SARS-CoV-2 provided high analytical performance for the detection of SARS-CoV-2 in anterior nasal samples and saliva samples.

**Introduction**

For the diagnosis of coronavirus disease 2019 (COVID-19), accurate and rapid laboratory testing is essential. Molecular examination using real-time reverse transcriptase polymerase chain reaction (RT-PCR) has been considered the gold standard for the identification of SARS-CoV-2 [1], and nasopharyngeal samples have been commonly used for the sample examination, which requires high-level personal protective equipment [2]. For COVID-19 testing, anterior nasal samples and saliva samples have been proposed as alternative samples [3], which can be easily obtained from patients.

GENECUBE® (TOYOBO Co., Ltd., Osaka, Japan) is a Qprobe-PCR-based automated rapid molecular identification system that can detect target genes in a short time and simultaneously analyze up to 12 samples and 4 assays in a single examination [4–9]. The system automatically performs molecular examination directly, including preparation of the reaction mixtures, and amplification and detection of target genes, in 30 minutes.

GENECUBE® HQ SARS-CoV-2 (TOYOBO Co., Ltd.) is the GENECUBE® reagent for detecting the SARS-CoV-2 gene in clinical samples. This reagent was currently approved by the Ministry of Health, Labour and Welfare in Japan in October 2020. We previously evaluated the performance of the assay using 1065 nasopharyngeal samples [10]. Compared with the reference RT-PCR assay, the overall positive- and negative concordance rates were 99.7% (95% confidence interval [CI]: 99.2%–99.9%), 100.0% (95% CI: 93.4%–100.0%) and 99.7% (95% CI: 99.1%–99.9%), respectively. All discordant samples were GENECUBE® HQ SARS-CoV-2-positive and reference RT-PCR-negative, and SARS-CoV-2 was detected by another molecular assay [10]. During the previous evaluation, samples other than nasopharyngeal samples were not used.

In the present study, we evaluated the diagnostic performance of the GENECUBE® HQ SARS-CoV-2 using anterior nasal samples and saliva samples. Additionally, we evaluated a new rapid examination protocol using GENECUBE® HQ SARS-CoV-2 for the detection of SARS-CoV-2.

**Materials and methods**

The current study was performed at a drive-through PCR center in Tsukuba Medical Center Hospital (TMCH) in Tsukuba, Ibaraki Prefecture, Japan, which intensively performed sample collecting and PCR analysis with nasopharyngeal samples in the Tsukuba district [10, 11]. Patients with and without symptoms were referred from nearby clinics and a local public health center. All of the asymptomatic patients had known contact histories with COVID-19 confirmed/suspected patients.

Anterior nasal samples were prospectively collected from COVID-19-suspected or COVID-19-confirmed patients in addition to nasopharyngeal samples between 11 May 2021 and 5 July 2021, as previously performed [12]. Saliva samples were also prospectively collected.
in addition to nasopharyngeal samples from COVID-19-confirmed patients between 21 April 2021 and 13 May 2021. All of anterior nasal samples and saliva samples from COVID-19-confirmed patients were obtained on the same day of nasopharyngeal sample collection.

Anterior nasal samples and saliva samples were simultaneously examined using GENE-CUBE® HQ SARS-CoV-2 (GENECUBE examination) and reference RT-PCR, and the concordance of the two methods was evaluated.

Informed consent was verbally obtained from patients for their participation in the respective part of the current research, and participant consent was documented in the electronic chart of each participant. Written informed consent was not obtained in order to avoid infection transmission through the consent forms. The ethics committee of Tsukuba Medical Center Hospital approved the present study (approval number: 2020–066) with the current protocol, including the method of obtaining informed consent.

This study was performed in line with the principles of the Declaration of Helsinki and adheres to the STARD reporting guidelines.

For negative saliva samples, residual frozen saliva samples collected during SARS-CoV-2 active screening at hospitalization in Tsukuba Medical Center Hospital were used for the current research after anonymization.

**Sample collection**

For anterior nasal samples, a nasopharyngeal-type flocked swab (Copan Italia SpA, Brescia, Italy) was inserted to a 2 cm depth in one nasal cavity, rotated five times, and held in place for 5 seconds. The swab samples were then diluted in 3 mL of UTM™ (Copan Italia SpA) immediately after sampling, and the UTM™ was then transferred to a microbiology laboratory located next to the drive-through sampling facility of the PCR center.

After arrival, purification, and ribonucleic acid (RNA) extraction were performed with magLEAD (Precision System Science Co., Ltd., Chiba, Japan) with 200 μL of fresh anterior nasal samples. RNA was eluted in 100 μL, which was used for the GENECUBE® examination and the reference RT-PCR examination. All saliva samples were stored at −80˚C and were purified with magLEAD after preparation (Fig 1). All of the GENECUBE® examinations and reference RT-PCR examinations were performed simultaneously on the same day.

**GENECUBE® examination with magLEAD and discrepancy analysis**

The sample used for the GENECUBE® examination analysis of SARS-CoV-2 was also used for the RT-PCR assays. All assays were performed with the previously described magLEAD conditions [10] (Fig 1). In addition to the standard protocol with magLEAD purification, a rapid protocol created by Hiromichi Suzuki, TOYOBO Co., Ltd. and Precision System Science Co., Ltd. were evaluated for saliva samples and samples for limit of detection (LOD) analysis. For the rapid protocol, in the preparation of saliva samples, purification and extraction processes were adjusted, and the total process time was shortened to approximately 10 minutes. The comparison of the standard protocol and the rapid protocol for each magLEAD purification processes is summarized in Table 1. The rapid protocol is commercially available in Japan as MagDEA Dx SV 200 for GENECUBE®.

If discordance was recognized between GENECUBE® and the reference RT-PCR, an additional evaluation was performed with Xpert® Xpress SARS-CoV-2 and GeneXpert® (Cepheid Inc., Sunnyvale, CA, USA) [15] analyses for anterior nasal samples according to the manufacturer’s instructions documented in the package insert, and with an RT-PCR with LightMix® Modular SARS-CoV (COVID19) E-gene (Roche Diagnostics KK) [16] for saliva samples along with re-evaluation with the NIID RT-PCR method.
Reference real-time RT-PCR method

Reference RT-PCR examinations were performed with purified samples using a method developed by the National Institute of Infectious Diseases (NIID), Japan, for SARS-CoV-2 [17, 18], which was used Briefly, 5 μL of the extracted RNA was used for one-step quantitative RT-PCR with the THUNDERBIRD® Probe One-step qRT-PCR kit (TOYOBO Co., Ltd.) and the LightCycler® 96 Real-time PCR System (Roche Diagnostics KK, Basel, Switzerland). A duplicate
analysis for N2 genes was performed for the evaluation of SARS-CoV-2. EDX SARS-CoV-2 Standard (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and sterile purified water (Merck & Co., Inc., Kenilworth, NJ, USA) were used as positive and negative controls, respectively. The calibration curves were generated with 5, 50 and 500 copies/reaction of EDX SARS-CoV-2 Standard.

Estimation of the limit of detection (LOD) for GENECUBE® HQ SARS-CoV-2 with nasopharyngeal samples and saliva samples

To estimate the LOD for GENECUBE® HQ SARS-CoV-2, we made four different concentrations of samples (2500 copies/mL, 1000 copies/mL, 500 copies/mL, 250 copies/mL) with SARS-CoV-2 reference material (AccuPlex™ SARS-CoV-2 Reference Material Kit, SeraCare; SeraCare Life Sciences, Inc., Milford, MA, USA) and matrix (UTM™; three pooled nasopharyngeal samples and two pooled saliva samples). In total, six samples were made at each concentration. The GENECUBE® examination was performed four times, and the reference RT-PCR was performed twice for each sample.

Statistical analyses

The positive-, negative-, and total concordance rates of the GENECUBE® examinations compared with the reference RT-PCR were calculated using the Clopper and Pearson methods with 95% confidence intervals. All calculations were conducted using the R 3.3.1 software program (The R Foundation, Vienna, Austria).

Results

Evaluation of LOD for the reference RT-PCR and GENECUBE® with SARS-CoV-2 reference material and pooled negative samples

The details of the results of the LOD evaluation for the three SARS-CoV-2 detection methods with SARS-CoV-2 reference material and pooled negative samples are listed in Table 2, summarized in Table 3 and S1 Fig.

The reference NIID real-time RT-PCR method showed positive results for all UTM-based samples (range: 250–5000 copies/mL), while the detection rate was 100% down to 1000 copies/mL for pooled nasopharyngeal samples and down to 2500 copies/mL for pooled saliva-based samples. None of the 500 copies/mL of pooled saliva-based samples and 250 copies/mL of pooled saliva-based samples were detected by the NIID real-time RT-PCR method.
Table 2. Detailed results of the estimated LOD test for three SARS-CoV-2 detection methods.

| Ratio of reference material and sample | Copies/mL | Sample                          | GENECUBE® (Standard method with magLEAD) | GENECUBE® (Rapid method with magLEAD) | Real-time RT-PCR (NIID method) |
|--------------------------------------|-----------|---------------------------------|------------------------------------------|--------------------------------------|------------------------------|
|                                      |           | N of detection/N of test (detection rate) |                                          | Ct value (Copies/test)               |
| reference material:                  | 2500      | Total                           | 24/24 (100)                               | 12/12 (100)                          | -                            |
| sample = 1:1                         |           | UTM                             | 4/4 (100)                                 | 2/2 (100)                            | 31.9 (48)/32.4 (34)          |
|                                     |           | Pooled nasopharyngeal sample 1  | 4/4 (100)                                 | 2/2 (100)                            | 32.2 (39)/31.9 (50)          |
|                                     |           | Pooled nasopharyngeal sample 2  | 4/4 (100)                                 | 2/2 (100)                            | 32.7 (28)/32.3 (36)          |
|                                     |           | Pooled nasopharyngeal sample 3  | 4/4 (100)                                 | 2/2 (100)                            | 32.2 (40)/32.4 (35)          |
|                                     |           | Pooled saliva sample 1          | 4/4 (100)                                 | 2/2 (100)                            | 32.3 (38)/32.5 (33)          |
|                                     |           | Pooled saliva sample 2          | 4/4 (100)                                 | 2/2 (100)                            | 32.3 (37)/32.7 (28)          |
| reference material:                  | 1000      | Total                           | 24/24 (100)                               | 10/12 (83)                           | -                            |
| sample = 1:4                         |           | UTM                             | 4/4 (100)                                 | 2/2 (100)                            | 34.1 (11)/33.5 (16)          |
|                                     |           | Pooled nasopharyngeal sample 1  | 4/4 (100)                                 | 2/2 (100)                            | 33.7 (15)/33.7 (15)          |
|                                     |           | Pooled nasopharyngeal sample 2  | 4/4 (100)                                 | 2/2 (100)                            | 33.5 (16)/33.6 (15)          |
|                                     |           | Pooled nasopharyngeal sample 3  | 4/4 (100)                                 | 2/2 (100)                            | 34.1 (11)/33.1 (21)          |
|                                     |           | Pooled saliva sample 1          | 4/4 (100)                                 | 1/2 (50)                             | 33.3 (19)/ND                 |
|                                     |           | Pooled saliva sample 2          | 4/4 (100)                                 | 1/2 (50)                             | 33.8 (14)/ND                 |
| reference material:                  | 500       | Total                           | 23/24 (96)                                | 4/12 (33)                            | -                            |
| sample = 1:9                         |           | UTM                             | 4/4 (100)                                 | 2/2 (100)                            | 34.5 (8)/35.3 (5)            |
|                                     |           | Pooled nasopharyngeal sample 1  | 4/4 (100)                                 | 0/2 (0)                              | ND/ND                       |
|                                     |           | Pooled nasopharyngeal sample 2  | 3/4 (75)                                  | 2/2 (100)                            | 34.3 (10)/34.2 (10)          |
|                                     |           | Pooled nasopharyngeal sample 3  | 4/4 (100)                                 | 0/2 (0)                              | ND/ND                       |
|                                     |           | Pooled saliva sample 1          | 4/4 (100)                                 | 0/2 (0)                              | ND/ND                       |
|                                     |           | Pooled saliva sample 2          | 4/4 (100)                                 | 0/2 (0)                              | ND/ND                       |
| reference material:                  | 250       | Total                           | 19/24 (79)                                | 3/12 (25)                            | -                            |
| sample = 1:19                        |           | UTM                             | 4/4 (100)                                 | 2/2 (100)                            | 36.2 (3)/34.8 (7)            |
|                                     |           | Pooled nasopharyngeal sample 1  | 4/4 (100)                                 | 0/2 (0)                              | ND/ND                       |
|                                     |           | Pooled nasopharyngeal sample 2  | 4/4 (100)                                 | 1/2 (50)                             | 35.1 (5)/ND                 |
|                                     |           | Pooled nasopharyngeal sample 3  | 2/4 (50)                                  | 0/2 (0)                              | ND/ND                       |
|                                     |           | Pooled saliva sample 1          | 3/4 (75)                                  | 0/2 (0)                              | ND/ND                       |
|                                     |           | Pooled saliva sample 2          | 2/4 (50)                                  | 0/2 (0)                              | ND/ND                       |

The Accuplex<sup>TM</sup> SARS-CoV-2 reference material (5000 copies/mL) was diluted with UTM or pooled samples and subjected to magLEAD extraction with the standard or rapid method. Each extract was then assayed four times by GENECUBE® and twice by NIID RT-PCR. 
Ct cycle threshold, LOD limit of detection, ND not detected, NIID National Institute of Infectious Diseases, RT-PCR reverse transcription polymerase chain reaction

https://doi.org/10.1371/journal.pone.0262159.t002
The standard protocols with magLEAD and GENECUBE® showed positive results for all UTM-based samples. The detection rate was 100% down to 1000 copies/mL for pooled nasopharyngeal-based samples and down to 500 copies/mL for pooled saliva-based samples. The detection rate of 500 copies/mL pooled nasopharyngeal-based samples was 91.7% (11/12).

For the rapid protocol with magLEAD and GENECUBE®, the method showed positive results for all UTM-based samples. The detection rate was 100% down to 500 copies/mL for pooled nasopharyngeal-based samples and pooled saliva-based samples.

**Comparison of the reference RT-PCR and GENECUBE® for the detection of SARS-CoV-2 with anterior nasal samples**

In this study, we prospectively evaluated 359 fresh anterior nasal samples, including 59 samples with positive SARS-CoV-2 results for simultaneously collected nasopharyngeal samples (cycle threshold (Ct) < 20, n = 40; Ct ≥ 20 to < 30, n = 16; Ct ≥ 30, n = 3) (S1 Table). Of the 359 anterior nasal samples, 298 (83.0%) were obtained from asymptomatic patients.

The comparison of the reference RT-PCR and GENECUBE® (standard protocol) for the detection of SARS-CoV-2 with anterior nasal samples is summarized in Tables 4–6. For anterior nasal samples prospectively obtained from suspected COVID-19 patients (Table 4), the total, positive and negative concordance of the 2 assays were 100% (320/320), 100% (18/18) and 100% (302/302), respectively. With the addition of the enriched positive patients, the total, positive and negative concordance of the 2 assays were 99.7% (358/359), 98.1% (51/52) and 99.7% (307/308), respectively.

**Table 3. Summary of the estimated LOD test results for three SARS-CoV-2 detection methods.**

| Sample (Copies/mL) | GENECUBE® (Standard method with magLEAD) | GENECUBE® (Rapid method with magLEAD) | Real-time RT-PCR (N2 NIID method) |
|---------------------|-----------------------------------------|---------------------------------------|----------------------------------|
|                     | N of detection/N of test (detection rate) | N of detection/N of test (detection rate) | N of detection/N of test (detection rate) |
| 2500                | 24/24 (100)                              | 24/24 (100)                           | 12/12 (100)                      |
| 1000                | 24/24 (100)                              | 24/24 (100)                           | 10/12 (83)                       |
| 500                 | 23/24 (96)                               | 24/24 (100)                           | 4/12 (33)                        |
| 250                 | 19/24 (79)                               | 18/24 (75)                            | 3/12 (25)                        |

LOD limit of detection, N number, NIID National Institute of Infectious Diseases, RT-PCR reverse transcription polymerase chain reaction

The standard protocols with magLEAD and GENECUBE® showed positive results for all UTM-based samples. The detection rate was 100% down to 1000 copies/mL for pooled nasopharyngeal-based samples and down to 500 copies/mL for pooled saliva-based samples. The detection rate of 500 copies/mL pooled nasopharyngeal-based samples was 91.7% (11/12).

For the rapid protocol with magLEAD and GENECUBE®, the method showed positive results for all UTM-based samples. The detection rate was 100% down to 500 copies/mL for pooled nasopharyngeal-based samples and pooled saliva-based samples.

**Table 4. Concordance rate of the GENECUBE® HQ SARS-CoV-2 with real-time RT-PCR for anterior nasal samples obtained from suspected COVID-19 patients.**

| Real-time RT-PCR (N2 NIID method) (Anterior nasal samples) | Positive | Negative |
|------------------------------------------------------------|----------|----------|
| Standard method with magLEAD extraction for GENECUBE® (Anterior nasal sample) | 18       | 0        |
| Positive concordance rate (%)                              | 100 (81.5–100) |
| Negative concordance rate (%)                              | 100 (98.8–100) |
| Total concordance rate (%)                                 | 100 (98.9–100) |

NIID National Institute of Infectious Diseases, RT-PCR reverse transcription polymerase chain reaction

Data in parentheses are 95% confidence intervals.
When GENECUBE® (standard protocol) with anterior nasal samples were compared with the reference RT-PCR with nasopharyngeal samples, the total, positive and negative concordance were 97.8% (351/359), 86.4% (51/59) and 100% (300/300), respectively.

Comparison of the reference RT-PCR and GENECUBE® for the detection of SARS-CoV-2 with saliva samples

For the comparison between the reference RT-PCR and GENECUBE® for the detection of SARS-CoV-2, 60 frozen samples (symptomatic patients, 32; asymptomatic patients, 28) obtained from confirmed COVID-19 patients by nasopharyngeal samples and 180 frozen negative saliva samples were examined.

The evaluation of the standard protocol with magLEAD and GENECUBE® is described in Table 7, and the evaluation of the rapid protocol with magLEAD and GENECUBE® is described in Table 8. The result of one sample was invalid initially by both GENECUBE® examinations, and the sample required four-fold dilution with lysis buffer for the GENECUBE® examinations.

For the evaluation of the standard protocol with magLEAD and GENECUBE® (Table 7), the total-, positive-, and negative concordance of the two assays was 99.6% (239/240), 100% (56/56), and 99.5% (183/184), respectively.

Table 5. Concordance rate of the GENECUBE® HQ SARS-CoV-2 with real-time RT-PCR for anterior nasal samples obtained from suspected or confirmed COVID-19 patients.

|                           | Real-time RT-PCR (N2 NIID method) (Anterior nasal samples) |
|---------------------------|-----------------------------------------------------------|
|                           | Positive | Negative |
| Standard method with magLEAD extraction for GENECUBE® (Anterior nasal sample) | Positive | 51 | 0 |
|                           | Negative | 1* | 307 |
| Positive concordance rate (%) | 98.1 (89.7–100) |
| Negative concordance rate (%) | 100 (98.8–100) |
| Total concordance rate (%) | 99.7 (98.5–100) |

NIID National Institute of Infectious Diseases, RT-PCR reverse transcription polymerase chain reaction

Data in parentheses are 95% confidence intervals.

*The discordant sample was tested by Xpert® Xpress SARS-CoV-2 and GeneXpert® and was positive.

https://doi.org/10.1371/journal.pone.0262159.t005

Table 6. Concordance rate between the GENECUBE® HQ SARS-CoV-2 with anterior nasal samples and real-time RT-PCR with nasopharyngeal samples, both of which were simultaneously obtained from suspected or confirmed COVID-19 patients.

|                           | Real-time RT-PCR (N2 NIID method) (Nasopharyngeal samples) |
|---------------------------|-----------------------------------------------------------|
|                           | Positive | Negative |
| Standard method with magLEAD extraction for GENECUBE® (Anterior nasal samples) | Positive | 51 | 0 |
|                           | Negative | 8 | 300 |
| Positive concordance rate (%) | 86.4 (75.0–94.0) |
| Negative concordance rate (%) | 100 (98.8–100) |
| Total concordance rate (%) | 97.8 (95.7–99.0) |

NIID National Institute of Infectious Diseases, RT-PCR reverse transcription polymerase chain reaction

Data in parentheses are 95% confidence intervals.

https://doi.org/10.1371/journal.pone.0262159.t006
For the evaluation of the rapid protocol with magLEAD and GENECUBE® (Table 8), the total-, positive-, and negative concordance of the two assays was 98.8% (237/240), 100% (56/56), and 98.4% (181/184), respectively.

**Discussion**

During the analytical evaluation with 359 anterior nasal samples and 240 saliva samples, the GENECUBE® evaluation with GENECUBE® HQ SARS-CoV-2 showed high concordance rates compared with the reference RT-PCR. The estimated LoDs study indicated that the GENECUBE® evaluation conducted with GENECUBE® HQ SARS-CoV-2 maintained a high analytical performance for nasopharyngeal samples and saliva samples, with detection successful for as little as 1000 copies/mL for both types of samples.

In the current study concerning the GENECUBE examination, the rapid method with magLEAD extraction showed equivalent analytical performance to the standard method, both in the estimated LOD study and the comparative study with reference via real-time RT-PCR. Of note, two saliva samples obtained from COVID-19Confirmed patients were positive with the rapid protocol and negative with the standard protocol. This slight difference might be due to differences in the centrifugation condition (Fig 1) and number of washes performed (Table 1), which can result in the loss of virus and RNA; however, the difference was not proven in the estimated LOD study, and the superiority with respect to the analytical performance cannot be concluded based on the present findings.

For the evaluation of the rapid protocol with magLEAD and GENECUBE® (Table 8), the total-, positive-, and negative concordance of the two assays was 98.8% (237/240), 100% (56/56), and 98.4% (181/184), respectively.

**Discussion**

During the analytical evaluation with 359 anterior nasal samples and 240 saliva samples, the GENECUBE® evaluation with GENECUBE® HQ SARS-CoV-2 showed high concordance rates compared with the reference RT-PCR. The estimated LoDs study indicated that the GENECUBE® evaluation conducted with GENECUBE® HQ SARS-CoV-2 maintained a high analytical performance for nasopharyngeal samples and saliva samples, with detection successful for as little as 1000 copies/mL for both types of samples.

In the current study concerning the GENECUBE examination, the rapid method with magLEAD extraction showed equivalent analytical performance to the standard method, both in the estimated LOD study and the comparative study with reference via real-time RT-PCR. Of note, two saliva samples obtained from COVID-19Confirmed patients were positive with the rapid protocol and negative with the standard protocol. This slight difference might be due to differences in the centrifugation condition (Fig 1) and number of washes performed (Table 1), which can result in the loss of virus and RNA; however, the difference was not proven in the estimated LOD study, and the superiority with respect to the analytical performance cannot be concluded based on the present findings.

**Table 7. Concordance rate of the standard method with magLEAD extraction for GENECUBE® with real-time RT-PCR for saliva samples.**

|                          | Real-time RT-PCR (N2 NIID method) |
|--------------------------|-----------------------------------|
|                          | Positive | Negative          |
| Rapid method with magLEAD extraction for GENECUBE® | Positive | 56 | 1** |
|                          | Negative | 0 | 183 |
| Positive concordance rate (%) | 100 (93.6–100) |
| Negative concordance rate (%) | 99.5 (97.0–100) |
| Total concordance rate (%) | 99.6 (97.7–100) |

NIID National Institute of Infectious Diseases, RT-PCR reverse transcription polymerase chain reaction.

Data in parentheses are 95% confidence intervals.

* 60 frozen samples obtained from confirmed COVID-19 patients by nasopharyngeal samples and 180 negative saliva samples were used.

**The discordant samples were tested by real-time RT-PCR with Roche LightMix Modular SARS and Wuhan CoV E-gene and all were positive (S3 Table).**

https://doi.org/10.1371/journal.pone.0262159.t007

**Table 8. Concordance rate of the rapid method with magLEAD extraction for GENECUBE® with real-time RT-PCR for saliva samples.**

|                          | Real-time RT-PCR (N2 NIID method) |
|--------------------------|-----------------------------------|
|                          | Positive | Negative          |
| Rapid method with magLEAD extraction for GENECUBE® | Positive | 56 | 3** |
|                          | Negative | 0 | 181 |
| Positive concordance rate (%) | 100 (93.6–100) |
| Negative concordance rate (%) | 98.4 (95.3–99.7) |
| Total concordance rate (%) | 98.8 (96.4–99.7) |

NIID National Institute of Infectious Diseases, RT-PCR reverse transcription polymerase chain reaction.

Data in parentheses are 95% confidence intervals.

* 60 frozen samples obtained from confirmed COVID-19 patients by nasopharyngeal samples and 180 negative saliva samples were used.

**The discordant samples were tested by real-time RT-PCR with Roche LightMix Modular SARS and Wuhan CoV E-gene and all were positive (S3 Table).**

https://doi.org/10.1371/journal.pone.0262159.t008
Saliva has been considered a good alternative for the detection of SARS-CoV-2 in COVID-19 patients [3] and has been widely used in COVID-19 practice. Among rapid molecular identification systems, GeneXpert® showed good analytical performance for the detection of SARS-CoV-2 with saliva samples [19]; however, the application of saliva to rapid molecular identification systems remains a challenge owing to saliva’s viscosity and RT-PCR inhibition. In our current study, we used 60 saliva samples with positive nasopharyngeal sample results for SARS-CoV-2 (S2 Table), and the rapid protocol detected SARS-CoV-2 in most samples (98.3%; 59/60). The rapid protocol can detect SARS-CoV-2 with high performance in approximately 35 minutes with saliva samples, and the protocol is expected to have clinical utility, especially for the rapid accurate identification of SARS-CoV-2-infected patients with collecting nasopharyngeal samples is considered difficult. The current study used frozen saliva samples for validation. While the analytical performance for the detection of SARS-CoV-2 has been reported to be equal between fresh and frozen saliva samples [20], the freeze-thaw method has been known as one of the RNA/DNA extraction methods [21] which might influence the sensitivity [22]. Therefore, a further evaluation should be performed with fresh samples.

Anterior nasal samples are also a good alternative method for COVID-19 sampling [3]. The method has been reported as less painful and induced fewer coughs or sneezes compared with nasopharyngeal sampling [12]. The application of self-collected anterior nasal sampling has also been reported [23]. In the current study, the analytical performance of the GENECUBE® examination was almost identical to the reference RT-PCR. However, there were seven negative results using anterior nasal samples, which were obtained from patients with positive nasopharyngeal samples (S1 Table). The detection rate was 88.1% (52/59), which was inferior to that with saliva samples; however, saliva samples were not simultaneously collected with anterior nasal samples in the present study, so we cannot compare the sensitivity. In addition, we obtained anterior nasal samples from a single nasal cavity; however, the viral loads obtained with nasal sampling differ between nares [24], so sampling from both nasal cavities is preferable [25].

There are several limitations in this study that should be mentioned. First, reference real-time RT-PCR was used for the comparison, and a discrepant analysis was used for the validation, which can cause bias unless a composite reference standard is used as a reference [26–32]. While the current study evaluated the concordance with the reference real-time RT-PCR findings, the sensitivity and specificity of the GENECUBE® examination were not accurately confirmed. Second, the current research was performed at a PCR center in Japan. The influence of LODs of the GENECUBE® evaluation for genetic variants of SARS-CoV-2 was not evaluated in this study. Third, the current evaluated rapid protocol showed excellent performance for the detection of SARS-CoV-2; however, the sample size was insufficient to conclude that the protocol can be used in clinical practice; additional evaluation in studies with large samples is required. Fourth, the current GENECUBE® examination can analyze only 12 samples at a single run, and the amplification curve is not displayed. The system must be improved for better examination. Fourth, for the evaluation of the GENECUBE® examination using anterior nasal samples, the proportion of low viral load samples (Ct ≥ 30) was small, which could have improved thus concordance rates of the current study.

In conclusion, the GENECUBE® examination with GENECUBE® HQ SARS-CoV-2 provided high analytical performance for the detection of SARS-CoV-2 in anterior nasal samples and saliva samples.

Supporting information

S1 Fig. Detection rate of three SARS-CoV-2 detection methods for each concentration of samples. The same set of samples was extracted with the standard or rapid method with magLEAD and analyzed with GENECUBE® and real-time RT-PCR (N2 NIID method) for
each sample concentration. The vertical axis shows the detection rate (%). The horizontal axis shows the comparison of each three SARS-CoV-2 detection methods, and each of the bar graph types shows the sample concentration.

(TIF)

S1 Table. Results of SARS-Cov-2 detection for anterior nasal samples.

(DOCX)

S2 Table. Results of SARS-Cov-2 detection for saliva samples.

(DOCX)

S3 Table. Detailed data for the three cases with discordant findings among the three SARS-CoV-2 detection methods for saliva samples.

(DOCX)

Acknowledgments

For their thorough support of this study, we are very grateful to Mrs. Yoko Ueda, Mrs. Mio Matsumoto, Mrs. Asami Nakayama, and the staff in the Department of the Clinical Laboratory of Tsukuba Medical Center Hospital. We thank all of the medical institutions for providing their patients’ clinical information.

Author Contributions

Conceptualization: Hiromichi Suzuki.

Data curation: Asami Naito, Yusaku Akashi, Akio Sugiyama, Masashi Michibuchi, Yuto Takeuchi, Shigeyuki Notake, Koji Nakamura, Hiromichi Suzuki.

Formal analysis: Yusaku Akashi, Akio Sugiyama, Masashi Michibuchi, Hiromichi Suzuki.

Funding acquisition: Hiromichi Suzuki.

Investigation: Asami Naito, Akio Sugiyama, Masashi Michibuchi, Yuto Takeuchi, Shigeyuki Notake, Koji Nakamura, Hiromichi Suzuki.

Methodology: Akio Sugiyama, Masashi Michibuchi, Hiromichi Suzuki.

Project administration: Asami Naito, Hiromichi Suzuki.

Resources: Hiromichi Suzuki.

Supervision: Yoshihiko Kiyasu, Hiroichi Ishikawa, Hiromichi Suzuki.

Validation: Asami Naito, Akio Sugiyama, Masashi Michibuchi, Hiromichi Suzuki.

Visualization: Asami Naito, Hiromichi Suzuki.

Writing – original draft: Asami Naito, Yoshihiko Kiyasu, Yusaku Akashi, Akio Sugiyama, Hiromichi Suzuki.

Writing – review & editing: Asami Naito, Yoshihiko Kiyasu, Yusaku Akashi, Akio Sugiyama, Masashi Michibuchi, Yuto Takeuchi, Shigeyuki Notake, Koji Nakamura, Hiroichi Ishikawa, Hiromichi Suzuki.

References

1. Hanson KE, Altayar O, Caliendo AM, Arias CA, Englund JA, Hayden MK, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing. Clin Infect Dis. 2021; ciab557. https://doi.org/10.1093/cid/ciab557 PMID: 34160592
2. Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen. N Engl J Med. 2020; 382: e76. https://doi.org/10.1056/NEJMvc2012060 PMID: 32302471

3. Tsang NNY, So HC, Ng KY, Cowling BJ, Leung GM, Ip DKM. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect Dis. 2021; 21: 1233–1245. https://doi.org/10.1016/S1473-3099(21)00146-8 PMID: 33857405

4. Hara T, Suzuki H, Oyanagi T, Koyanagi N, Ushiki A, Kawabata N, et al. Clinical evaluation of a non-purified direct molecular assay for the detection of Clostridioides difficile toxins in stool specimens. PLoS One. 2020; 15:e0234119. https://doi.org/10.1371/journal.pone.0234119 PMID: 32492051

5. Nagura-Ikedo M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, et al. Clinical Evaluation of Self-Collected Saliva for Quantitative Reverse Transcription-PCR (RT-qPCR) for SARS-CoV-2. J Med Microbiol. 2020; 69: 1346–1350. https://doi.org/10.1099/jmm.0.001264 PMID: 33141009

6. Hida Y, Uemura K, Sugimoto H, Kawashima Y, Koyanagi N, Notake S, et al. Evaluation of performance of the GENECUBE® assay for rapid molecular identification of Staphylococcus aureus and methicillin resistance in positive blood culture medium. PLoS One. 2019; 14: e0219819. https://doi.org/10.1371/journal.pone.0219819 PMID: 31310615

7. Ito Y, Iwashima S, Hayano N, Nishio T, Shiozawa R, Yata S, et al. Rapid detection of the macrolide sensitivity of pneumonia-causing Mycoplasma pneumoniae using quenching probe polymerase chain reaction (GENECUBE®). Mol Diagn Ther. 2018; 22: 737–747. https://doi.org/10.1007/s40291-018-0360-x PMID: 30259422

8. Miyazaki N, Yamagishi Y, Izumi K, Kawashima Y, Suematsu H, Mikamo H. Evaluation of rapid measurement of Chlamydia trachomatis and Neisseria gonorrhoeae by using automatic gene analyzer "GENECUBE®". Jpn J Antibiot. 2016; 69: 291–298. PMID: 30226955

9. Morinaga Y, Suzuki H, Notake S, Mizusaka T, Uemura K, Otomo S, et al. Evaluation of GENECUBE Mycoplasma for the detection of macrolide-resistant Mycoplasma pneumoniae. J Med Microbiol. 2020; 69: 1346–1350. https://doi.org/10.1099/jmm.0.001264 PMID: 33141009

10. Kiyasu Y, Akashi Y, Sugiyama A, Takeuchi Y, Notake S, Naito A, et al. A prospective evaluation of the analytical performance of GENECUBE® HQ SARS-CoV-2 and GENECUBE® FLU A/B. Mol Diag Ther. 2021; 25: 495–504. https://doi.org/10.1007/s40291-021-00535-5 PMID: 34003471

11. Kiyasu Y, Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, et al. Prospective analytical performance evaluation of the QuickNavi™-COVD19 Ag for asymptomatic individuals. J Infect Chemother. 2021; 10: 1489–1492. https://doi.org/10.1016/j.jiac.2021.07.005 PMID: 34304185

12. Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, et al. Diagnostic performance and characteristics of anterior nasal collection for the SARS-CoV-2 antigen test: a prospective study. Sci Rep. 2021; 11; 10519. https://doi.org/10.1038/s41598-021-90026-8 PMID: 34006975

13. Precision System Science Co., Ltd. magLEAD 6gC & magLEAD 12gC High-Quality, Low Cost, Automated Nucleic Acid Extraction System. 2021 [Cited 5 August 2021]. Available from https://www.pss.co.jp/product/magtration/lead6-12gc.html

14. TOYOBO Co., Ltd. Fully Automated Gene Analyzer GENECUBE® (model C). 2021 [Cited 5 August 2021]. Available from https://www.yoobaco.jp/products/bio/gene/genecube_c_index.html.

15. Loeffelholz MJ, Alland D, Butler-Wu SM, Pandey U, Perno CF, Nava A, et al. Multicenter evaluation of the Cepheid Xpert Xpress SARS-CoV-2 test. J Clin Microbiol. 2020; 58: e00926–20. https://doi.org/10.1128/JCM.00926-20 PMID: 32666669

16. Mizoguchi M, Harada S, Okamoto K, Higurashi Y, Ikeda M, Moriya K. Comparative performance and cycle threshold values of 10 nucleic acid amplification tests for SARS-CoV-2 on clinical samples. PLoS One. 2021; 16: e0252757. https://doi.org/10.1371/journal.pone.0252757 PMID: 34161355

17. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Development of genetic diagnostic methods for detection of novel coronavirus 2019(nCoV-2019) in Japan. Jpn J Infect Dis. 2020; 73: 304–307. https://doi.org/10.7883/yoken.JJID.2020.06.01 PMID: 32074516

18. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, et al. Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR) for SARS-CoV-2. J Med Microbiol. 2020; 58: e01438–20. https://doi.org/10.1099/jmm.0.01438-20 PMID: 32636214

19. McCormick-Baw C, Morgan K, Gaffney D, Cazares Y, Jaworski K, Byrd A, et al. Saliva as an alternate specimen source for detection of SARS-CoV-2 in symptomatic patients using Cepheid Xpert Xpress SARS-CoV-2. J Clin Microbiol. 2020; 58: e01109–20. https://doi.org/10.1128/JCM.01109-20 PMID: 32414838

20. Fukumoto T, Iwasaki S, Fujisawa S, Hayasaka K, Sato K, Oguri S, et al. Efficacy of a novel SARS-CoV-2 detection kit without RNA extraction and purification. Int J Infect Dis. 2020; 98: 16–17. https://doi.org/10.1016/j.ijid.2020.06.074 PMID: 32599282
21. Paz S, Mauer C, Ritchie A, Robishaw JD, Caputi M. A simplified SARS-CoV-2 detection protocol for research laboratories. PLoS One. 2020; 15: e0244271. https://doi.org/10.1371/journal.pone.0244271 PMID: 3338082

22. Ott IM, Strine MS, Watkins AE, Boot M, Kalinch CC, Harden CA, et al. Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices. medRxiv: 20165233v1. [Preprint]. 2020 [Cited 2020 August 4]. Available from: https://www.medrxiv.org/content/10.1101/2020.08.03.20165233v1. https://doi.org/10.1101/2020.08.03.20165233 PMID: 32793924

23. Marx GE, Biggerstaff BJ, Nawrocki CC, Totten SE, Travanty EA, Burakoff AW, et al. SARS-CoV-2 detection on self-collected saliva or anterior nasal specimens compared with healthcare personnel-collected nasopharyngeal specimens. Clin Infect Dis. 2021; 73(Suppl 1): S65–S73. https://doi.org/10.1093/cid/cia_b330 PMID: 33912930

24. van Wesenbeeck L, Meeuws H, D’Haese D, Ispas G, Houspie L, van Ranst M, et al. Sampling variability between two mid-turbinate swabs of the same patient has implications for influenza viral load monitoring. Virology Journal. 2014; 11. https://doi.org/10.1186/s12985-014-0233-9 PMID: 25539740

25. SARS-CoV-2 (COVID-19) Fact Sheet. Nasal (Anterior Nasal) Specimen Collection for SARS-CoV-2 Diagnostic Testing. Centers for Disease Control and Prevention. 2021 [Cited 20 August 2021]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/downloads/OASH-nasal-specimen-collection-fact-sheet.pdf

26. Miller WC. Bias in discrepant analysis: When two wrongs don’t make a right. Journal of Clinical Epidemiology. 1998; 51: 219–231. https://doi.org/10.1016/s0895-4356(97)00264-3 PMID: 9495687

27. Hadgu A. Discrepant analysis: A biased and an unscientific method for estimating test sensitivity and specificity. Journal of Clinical Epidemiology. 1999; 52: 1231–1237. https://doi.org/10.1016/s0895-4356(99)00101-8 PMID: 10580787

28. Hadgu A. The discrepancy in discrepant analysis. Lancet. 1996; 348: 592–593. https://doi.org/10.1016/S0140-6736(96)00122-7 PMID: 8774575

29. McAdam AJ. Discrepant analysis and bias: A micro-comic strip. Journal of Clinical Microbiology. American Society for Microbiology; 2017; 55: 2878–2879. https://doi.org/10.1128/JCM.00969-17 PMID: 28947507

30. Hadgu A. Discrepant analysis is an inappropriate and unscientific method. Journal of Clinical Microbiology. 2000; 38: 4301–4302. https://doi.org/10.1128/JCM.38.11.4301-4302.2000 PMID: 11142698

31. Miller WC. Editorial Response: Can we do better than discrepant analysis for new diagnostic test evaluation?. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 1998; 27: 1186–1193. https://doi.org/10.1086/514996 PMID: 9827267

32. Green TA, Black CM, Johnson RE. Evaluation of bias in diagnostic-test sensitivity and specificity estimates computed by discrepant analysis. Journal of Clinical Microbiology. 1998; 36: 375–381. https://doi.org/10.1128/JCM.36.2.375-381.1998 PMID: 9466744